1. At a Glance
Authum Investment & Infrastructure is not your average NBFC — it’s a fund-based powerhouse pouring cash into stocks, PE, real estate, and secured lending. From ₹3,186 crore investments in FY22 to a jaw-dropping ₹10,317 crore in Q2 FY25, they’re basically the Wall Street of India’s midcap segment. Market cap? A hefty ₹48,760 crore, with a P/E under 12 signaling a mix of growth and value. ROCE and ROE are stellar — 31% and 34% respectively — yet the tax rate is suspiciously low, raising eyebrows among auditors and cynics alike.
2. Introduction
Authum is a financial behemoth playing multiple games simultaneously: equity investing, real estate, debt financing, and structured credit. Unlike traditional NBFCs which chase loans and interest margins, Authum’s primary business is deploying capital in other companies and assets — think a private equity fund with an NBFC wrapper.
In a booming Indian economy with rising capital flows, Authum’s explosive investment book and 209% profit CAGR over five years make it a fascinating growth story. But the complexity of its portfolio and low effective tax rate mean investors need to dig deep, not just glance at the headline numbers.
3. Business Model (WTF Do They Even Do?)
Authum collects funds (from retail, institutional investors, and debt markets), then invests them across publicly listed and unlisted companies, private equity, real estate projects, and debt instruments. It also provides secured lending and structured financing products.
Its core revenue streams are dividends, interest income, and capital gains from its diverse investment book. The NBFC license allows it to raise debt at scale, amplifying returns. Recent acquisitions and stakes in companies like Kerala Ayurveda and ISARC hint at a mix of financial and operational control investments.
4. Financials Overview
- Investment Book: ₹10,317 crore (Q2 FY25), up 3x+ from ₹3,186 crore in FY22.
- Market Cap: ₹48,760 crore.
- P/E: 11.9x — surprisingly low given growth, suggesting some value.
- Revenue: Highly volatile — investment income can spike or dip with markets.
- PAT: ₹4,096 crore TTM, showing massive earnings growth but some quarterly volatility (e.g., -13.86% Q profit var recently).
- ROCE: 31.2% — exceptional for financial sector.
- ROE: 34.1% — healthy and consistent with high returns on equity.
- Debt: Virtually debt-free, lending credence to strong financial health.
5. Valuation
- P/E of 11.9x is attractive for a company growing earnings at 200%+ CAGR over 5 years.
- CMP/Book Value: 3.33x — a premium but reasonable given return ratios.
- Discounted Cash Flow: Complex due to volatile investment returns but current multiples suggest undervaluation if growth sustains.
- Peer comparison: Lower valuation than Bajaj Finance and Shriram Finance, despite higher ROE — likely due to complexity and market skepticism.
6. What’s Cooking – News, Triggers, Drama
- Recent acquisitions include 60.95% in Katra Phytochem, 88.37% in ISARC, and significant stakes in Kerala Ayurveda and OneSource Specialty Pharma — aggressive portfolio build.
- Promoters sold 3.41% stake for ₹1,290 crore but reinvested proceeds as low-cost debt, a strategic capital recycling move.
- Board changes and preferential share allotments hint
